Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger
1. NLS Pharmaceutics and Kadimastem's merger is now SEC effective. 2. The merger will create NewCelX Ltd. focusing on CNS disorders. 3. Kadimastem is set to begin a Phase 2a trial for ALS treatment. 4. The merger enhances access to U.S. capital markets for both companies. 5. Diversification in therapy approaches broadens candidate pipeline for the new entity.